104 related articles for article (PubMed ID: 38740965)
1. CXCR4 chemokine antagonist scores a first FDA approval for WHIM syndrome.
Mullard A
Nat Rev Drug Discov; 2024 Jun; 23(6):411. PubMed ID: 38740965
[No Abstract] [Full Text] [Related]
2. CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agent.
Wang J; Tannous BA; Poznansky MC; Chen H
Pharmacol Res; 2020 Sep; 159():105010. PubMed ID: 32544428
[TBL] [Abstract][Full Text] [Related]
3. Genetics on a WHIM.
Al Ustwani O; Kurzrock R; Wetzler M
Br J Haematol; 2014 Jan; 164(1):15-23. PubMed ID: 24111611
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor on a WHIM - Promise or Fantasy of a New CXCR4 Inhibitor for This Rare, but Important Syndrome?
Merati N; Sivachandran S; Jfri A; Ben-Shoshan M; Vinh DC; Popradi G; Litvinov IV
Skin Therapy Lett; 2022 Mar; 27(2):1-5. PubMed ID: 35385630
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome.
Dotta L; Tassone L; Badolato R
Curr Mol Med; 2011 Jun; 11(4):317-25. PubMed ID: 21506920
[TBL] [Abstract][Full Text] [Related]
6. Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.
De Clercq E
Antivir Chem Chemother; 2019; 27():2040206619829382. PubMed ID: 30776910
[TBL] [Abstract][Full Text] [Related]
7. AMD3100 is a potent antagonist at CXCR4(R334X) , a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome.
McDermott DH; Lopez J; Deng F; Liu Q; Ojode T; Chen H; Ulrick J; Kwatemaa N; Kelly C; Anaya-O'Brien S; Garofalo M; Marquesen M; Hilligoss D; DeCastro R; Malech HL; Murphy PM
J Cell Mol Med; 2011 Oct; 15(10):2071-81. PubMed ID: 21070597
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor.
McDermott DH; Liu Q; Velez D; Lopez L; Anaya-O'Brien S; Ulrick J; Kwatemaa N; Starling J; Fleisher TA; Priel DA; Merideth MA; Giuntoli RL; Evbuomwan MO; Littel P; Marquesen MM; Hilligoss D; DeCastro R; Grimes GJ; Hwang ST; Pittaluga S; Calvo KR; Stratton P; Cowen EW; Kuhns DB; Malech HL; Murphy PM
Blood; 2014 Apr; 123(15):2308-16. PubMed ID: 24523241
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic drugs in combination with the CXCR4 antagonist AMD3100 as a potential treatment option for pediatric rhabdomyosarcoma.
Regenbogen S; Stagno MJ; Schleicher S; Schilbach K; Bösmüller H; Fuchs J; Schmid E; Seitz G
Int J Oncol; 2020 Jul; 57(1):289-300. PubMed ID: 32377699
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation.
Gallego C; Vétillard M; Calmette J; Roriz M; Marin-Esteban V; Evrard M; Aknin ML; Pionnier N; Lefrançois M; Mercier-Nomé F; Bertrand Y; Suarez F; Donadieu J; Ng LG; Balabanian K; Bachelerie F; Schlecht-Louf G
Blood; 2021 May; 137(20):2770-2784. PubMed ID: 33512478
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CXCR4 and CXCR7 Is Protective in Acute Peritoneal Inflammation.
Ngamsri KC; Jans C; Putri RA; Schindler K; Gamper-Tsigaras J; Eggstein C; Köhler D; Konrad FM
Front Immunol; 2020; 11():407. PubMed ID: 32210974
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome.
Dale DC; Firkin F; Bolyard AA; Kelley M; Makaryan V; Gorelick KJ; Ebrahim T; Garg V; Tang W; Jiang H; Skerlj R; Beaussant Cohen S
Blood; 2020 Dec; 136(26):2994-3003. PubMed ID: 32870250
[TBL] [Abstract][Full Text] [Related]
13. A WHIM satisfactorily addressed.
Broxmeyer HE
Blood; 2014 Apr; 123(15):2286-8. PubMed ID: 24723677
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor CXCR4 oligomerization is disrupted selectively by the antagonist ligand IT1t.
Ward RJ; Pediani JD; Marsango S; Jolly R; Stoneman MR; Biener G; Handel TM; Raicu V; Milligan G
J Biol Chem; 2021; 296():100139. PubMed ID: 33268380
[TBL] [Abstract][Full Text] [Related]
15. The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.
McDermott DH; Liu Q; Ulrick J; Kwatemaa N; Anaya-O'Brien S; Penzak SR; Filho JO; Priel DA; Kelly C; Garofalo M; Littel P; Marquesen MM; Hilligoss D; Decastro R; Fleisher TA; Kuhns DB; Malech HL; Murphy PM
Blood; 2011 Nov; 118(18):4957-62. PubMed ID: 21890643
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor for the Treatment of WHIM Syndrome.
McDermott DH; Pastrana DV; Calvo KR; Pittaluga S; Velez D; Cho E; Liu Q; Trout HH; Neves JF; Gardner PJ; Bianchi DA; Blair EA; Landon EM; Silva SL; Buck CB; Murphy PM
N Engl J Med; 2019 Jan; 380(2):163-170. PubMed ID: 30625055
[TBL] [Abstract][Full Text] [Related]
17. Pathway and mechanism of drug binding to chemokine receptors revealed by accelerated molecular simulations.
Pawnikar S; Miao Y
Future Med Chem; 2020 Jul; 12(13):1213-1225. PubMed ID: 32515227
[No Abstract] [Full Text] [Related]
18. Posttransplant blockade of CXCR4 improves leukemia complete remission rates and donor stem cell engraftment without aggravating GVHD.
Su L; Fang MH; Zou J; Gao SJ; Gu XY; Meng XD; Wang X; Hu Z; Yang YG
Cell Mol Immunol; 2021 Nov; 18(11):2541-2553. PubMed ID: 34635806
[TBL] [Abstract][Full Text] [Related]
19. A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
McDermott DH; Velez D; Cho E; Cowen EW; DiGiovanna JJ; Pastrana DV; Buck CB; Calvo KR; Gardner PJ; Rosenzweig SD; Stratton P; Merideth MA; Kim HJ; Brewer C; Katz JD; Kuhns DB; Malech HL; Follmann D; Fay MP; Murphy PM
J Clin Invest; 2023 Oct; 133(19):. PubMed ID: 37561579
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
